← Retour à la une
États-Unis · Plateformes & données · MarketBeat

Ultragenyx Pharmaceutical Inc. (RARE) - What Are Investment Firms Saying About This Stock?

Publié par MarketBeat · États-Unis il y a 27 min
Image from MarketBeat Media, LLC.
Image from MarketBeat Media, LLC. · MarketBeat

Résumé détaillé

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has received an average recommendation of "Hold" from the twenty-two research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a ho

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

À lire aussi

MarketWatch

Nvidia is gearing up for one of Wall Street’s most anticipated earnings calls in years

 Seeking Alpha

Huang weighs Nvidia return as investors urge board to keep options open

 Investing.com

Tanker in New Orleans ship collision suffered ’steering casualty,’ NTSB says

 CNBC

Lutnick faces questions over Nvidia spy scandal. His sons' firm has ties to the chipmaker

 Yahoo Finance

Berry Street Welcomes MyScribe Founder Dr. Wasif Bokhari to Its AI Team and Acquires MyScribe

 TipRanks

Fonterra Shareholders’ Fund Annual Meeting Covers FY26 Results and Mainland Divestment